A pilot phase I dose escalation study of the EGFR tyrosine kinase inhibitor gefitinib (Iressa) combined with paclitaxel (Taxol) and external beam radiation therapy in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).

Trial Profile

A pilot phase I dose escalation study of the EGFR tyrosine kinase inhibitor gefitinib (Iressa) combined with paclitaxel (Taxol) and external beam radiation therapy in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2012

At a glance

  • Drugs Gefitinib (Primary) ; Paclitaxel (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 14 Mar 2012 Actual end date changed from Oct 2010 to Nov 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top